| Anticytokine therapy impacting on B cells in autoimmune diseases. | |
| | |
MedLine Citation:
|
PMID: 19346949 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
PURPOSE OF REVIEW: To evaluate the impact of particular anticytokine therapies able to indirectly target B cells with emphasis on the tumor necrosis factor (TNF) family members, B cell activating factor/B lymphocyte stimulator (BAFF/BLyS) and a proliferation-inducing ligand (APRIL). RECENT FINDINGS: Although blockade of TNF/lymphotoxin by etanercept has been shown to have an impact on memory B cells, recent studies of inhibiting the TNF family members BAFF/BlyS or simultaneously blocking BAFF/BlyS and APRIL in rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE) clearly demonstrated biologic activity, including reductions of immunoglobulin levels. However, clear evidence of clinical activity by any of the compounds interfering with BAFF/BLys or APRIL has not yet been shown. SUMMARY: Although anticytokine therapies mainly blocking signaling pathways of innate immunity, that is TNF-alpha, have shown efficacy in the treatment of arthritides and have partial effects on memory B cells, current studies evaluate effects on adaptive immunity by blocking BAFF/BlyS and/or APRIL which indirectly act on B and plasma cells. |
| | |
Authors:
|
Capucine Daridon; Gerd R Burmester; Thomas Dörner |
Related Documents
:
|
20196869 - Urokinase-type plasminogen activator and arthritis progression: role in systemic diseas... 21377379 - Harnessing dendritic cells for immunotherapy. 20131259 - Mast cell-derived tryptase inhibits apoptosis of human rheumatoid synovial fibroblasts ... 21178439 - Fungal hydrophobins form a sheath preventing immune recognition of airborne conidia. 21282509 - Conventional dendritic cells mount a type i ifn response against candida spp. requiring... 125289 - Immune complexes in sera and synovial fluids of patients with rheumatoid arthritis. rad... 19841639 - Reverse signaling through baff differentially regulates the expression of inflammatory ... 15849849 - Increased th1 and th2 immune reactivity with relative th2 dominance in patients with ac... 15748909 - Simulating the impact of a molecular 'decision-process' on cellular phenotype and multi... |
Publication Detail:
|
Type: Journal Article; Research Support, Non-U.S. Gov't; Review |
Journal Detail:
|
Title: Current opinion in rheumatology Volume: 21 ISSN: 1531-6963 ISO Abbreviation: Curr Opin Rheumatol Publication Date: 2009 May |
Date Detail:
|
Created Date: 2009-04-23 Completed Date: 2009-07-13 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 9000851 Medline TA: Curr Opin Rheumatol Country: United States |
Other Details:
|
Languages: eng Pagination: 205-10 Citation Subset: IM |
Affiliation:
|
Department of Rheumatology and Clinical Immunology, Charité University Medicine Berlin and Deutsches, Rheumaforschungszentrum, Berlin 10098, Germany. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Antibodies, Monoclonal
/
therapeutic use Arthritis, Rheumatoid / immunology, therapy Autoimmune Diseases / immunology*, therapy* B-Cell Activating Factor / antagonists & inhibitors B-Lymphocytes / immunology* Cytokines / antagonists & inhibitors* Humans Immunotherapy / methods Lupus Erythematosus, Systemic / immunology, therapy Models, Immunological Recombinant Fusion Proteins / therapeutic use Tumor Necrosis Factor Ligand Superfamily Member 13 / antagonists & inhibitors |
| Chemical | |
Reg. No./Substance:
|
0/Antibodies, Monoclonal; 0/B-Cell Activating Factor; 0/Cytokines; 0/Recombinant Fusion Proteins; 0/TACI receptor-IgG Fc fragment fusion protein; 0/TNFSF13 protein, human; 0/TNFSF13B protein, human; 0/Tumor Necrosis Factor Ligand Superfamily Member 13; 356547-88-1/belimumab |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Antipsychotics in the early stage of development.
Next Document: Novel screening tools for latent tuberculosis: time to leave an old friend?